article · Current Nanomedicine
The complexity of the management of cancerous conditions requires innovative strategies, including the pharmacotechnical optimization of treatments. The improvement of galenic forms, or more generally of drug delivery, represents a rapidly developing area of research, particularly in oncology, in order to remedy side effects and drug resistance remains a worrying problem. Carbon nanotubes CNTs consist of thin sheets of benzene carbons coiled into a seamless tubular structure. These CNTs have remarkable size and surface properties that make them the ideal vehicle for targeted and selective drug delivery. Different <i>in vitro</i> and <i>in vivo</i> experiments have proven that these particles can be easily modified in such a way that the chemical drug can be delivered directly to the tumor site. Additionally, different types of ligands can be loaded on the surface of CNTs to improve selectivity or modulate drug release. On the other hand, advances in carbon nanotubes could well lead to a more effective understanding of biological and physicochemical processes. This will make it possible to find compounds more compatible with carbon nanotube technology and facilitate their use.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2174/0124681873312144240620110052
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.